{
    "2020-06-28": [
        [
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196.HK)：拟为控股子公司复星实业提供担保 大额借贷担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "控股子公司",
                        "复星实业",
                        "担保",
                        "大额借贷"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196.HK)：FCN-159片用于I型神经纤维瘤的治疗获批开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-159片",
                        "I型神经纤维瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196)：FCN-159片用于I型神经纤维瘤的治疗获批开展I期临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-159片",
                        "I型神经纤维瘤",
                        "I期临床试验"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(02196)拟为复星实业5000万美元融资额度提供担保 大额借贷担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复星实业",
                        "5000万美元",
                        "融资额度",
                        "担保"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "一批新药将上市：恒瑞、赛诺菲、默沙东…",
                "features": {
                    "keywords": [
                        "新药",
                        "恒瑞",
                        "赛诺菲",
                        "默沙东"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "医药生物行业周报：拥抱药物创新和器械创新大时代",
                "features": {
                    "keywords": [
                        "医药生物",
                        "药物创新",
                        "器械创新"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "【关注】上半年药企人事密集变动",
                "features": {
                    "keywords": [
                        "药企",
                        "人事变动"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：FCN-011胶囊用于实体瘤治疗获批开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-011胶囊",
                        "实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：FCN-159片用于I型神经纤维瘤的治疗获批开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-159片",
                        "I型神经纤维瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：国家药监局同意FCN-159片开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-159片",
                        "国家药监局",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}